Transthyretin-mediated (ATTR) amyloidosis is a multisystem disease caused by the abnormal deposition of misfolded transthyretin protein as amyloid fibrils in various tissues. ATTR amyloidosis presents ...

This rare condition can’t be cured, but its symptoms can be treated. Take this assessment to learn what more you can do to manage the condition. Before you were diagnosed with transthyretin ...

In this opening episode titled, ‘Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges,’ moderator, Dr. Ryan Haumschild, and panelist, Dr. Kevin Alexander, ...

US FDA lifts clinical hold of Intellia Therapeutics’ MAGNITUDE phase 3 trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy: Cambridge, Massachusetts W ...

Credit: Alnylam. The approval for the ATTR-CM indication was supported by data from the HELIOS-B study. Treatment with vutrisiran led to a statistically significant reduction in the composite of ...

A research team at Kumamoto University has discovered that a natural compound found in pomegranate leaves and branches can ...

Intellia said the FDA removed the clinical hold on application for the Phase 3 clinical trial of nexiguran ziclumeran. The study is a randomized, double-blind, placebo-controlled trial evaluating the ...

Please provide your email address to receive an email when new articles are posted on . Amyloidosis is a disease in which specific precursor proteins misfold into beta-pleated sheets. Misfolded ...

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...